Comparing Intuitive Surgical (ISRG) and Pulse Biosciences (PLSE)

Intuitive Surgical (NASDAQ: ISRG) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Valuation & Earnings

This table compares Intuitive Surgical and Pulse Biosciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intuitive Surgical $3.13 billion 14.43 $660.00 million $5.68 70.77
Pulse Biosciences N/A N/A -$9.51 million ($1.39) -12.61

Intuitive Surgical has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and Pulse Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intuitive Surgical 21.09% 19.93% 17.02%
Pulse Biosciences N/A -62.10% -57.47%

Risk & Volatility

Intuitive Surgical has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.

Insider and Institutional Ownership

36.8% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 9.3% of Pulse Biosciences shares are owned by institutional investors. 2.2% of Intuitive Surgical shares are owned by company insiders. Comparatively, 6.7% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Intuitive Surgical and Pulse Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intuitive Surgical 0 5 12 0 2.71
Pulse Biosciences 0 0 0 0 N/A

Intuitive Surgical presently has a consensus price target of $406.13, indicating a potential downside of 0.66%. Given Intuitive Surgical’s higher possible upside, equities research analysts plainly believe Intuitive Surgical is more favorable than Pulse Biosciences.

Summary

Intuitive Surgical beats Pulse Biosciences on 10 of the 11 factors compared between the two stocks.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company’s da Vinci Surgical System consists of a surgeon’s console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon’s hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition (HD) vision. Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company’s instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply